For moderately severe active Crohn’s disease and fistula Crohn’s disease, the first dose of 5mg/kg should be given, and then the same dose should be given at week 2 and week 6 after the first dose and at 8-week intervals thereafter. For patients who do not respond well to the treatment, an adjustment of the dose to l0mg/kg may be considered, and the usual course of treatment is about 2 months, depending on the severity of the disease. The full name of infliximab is infliximab for injection. For patients with moderately severe active Crohn’s disease enteritis who are not responding well to conventional treatments, this product can be used to reduce signs and symptoms, and to achieve and maintain clinical efficacy. It promotes mucosal healing, improves quality of life, and allows patients to reduce glucocorticoid dosage or discontinue glucocorticoid use. In patients with fistulae Crohn’s disease, this product may be used to reduce the number of entero-cutaneous fistulas and rectal-vaginal fistulas, to promote and maintain fistula healing, to reduce signs and symptoms, and to improve quality of life. Common adverse reactions include infusion reactions, delayed anaphylactoid reactions, infections, and congestive heart failure. It is contraindicated in patients who are allergic to murine proteins or other components of the product. In patients with moderate to severe heart failure, administration of this product may increase the rate of hospitalization and mortality due to exacerbation of heart failure. All of the above medications should be used under the supervision of a physician, avoid self-medication.